# Outlook Therapeutics (OTLK) — Earnings

OTLK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/otlk/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.14 |
| EPS estimate | −$0.08 |
| EPS surprise | −75.00% |
| Revenue surprise | −99.07% |
| Revenue | $9,000.00 |
| Revenue estimate | $966,667.00 |
| Reported | Aug 14, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/468e6ca3-377c-a9a7-2f69-07c1b35f5d05.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2026 | Aug 14, 2026 | −$0.08 | −$0.14 | -75.00% | $966,667.00 | $9,000.00 |
| Q4 2025 | Dec 19, 2025 | −$0.26 | −$0.06 | 76.92% | $5.8M | — |
| Q3 2025 | Aug 14, 2025 | −$0.35 | −$0.44 | -24.82% | $1.5M | $1.5M |
| Q2 2025 | May 15, 2025 | −$0.54 | −$0.40 | 26.31% | $628,250.00 | — |
| Q1 2025 | Feb 14, 2025 | −$0.76 | −$0.89 | -17.11% | — | — |
| Q4 2024 | Dec 27, 2024 | −$0.80 | −$0.88 | -9.55% | — | — |
| Q3 2024 | Aug 14, 2024 | −$1.03 | −$0.83 | 19.64% | — | — |
| Q2 2024 | May 15, 2024 | −$0.91 | −$1.55 | -70.35% | — | — |
| Q1 2024 | Feb 14, 2024 | −$0.99 | −$0.80 | 19.57% | — | — |
| Q4 2023 | Dec 22, 2023 | −$1.15 | −$1.00 | 13.04% | $2.5M | — |
| Q3 2023 | Aug 14, 2023 | −$1.05 | −$1.60 | -52.38% | — | — |
| Q2 2023 | May 15, 2023 | −$1.28 | −$0.60 | 53.18% | — | — |
| Q1 2023 | Feb 14, 2023 | −$1.19 | −$1.60 | -34.45% | — | — |
| Q4 2022 | Dec 29, 2022 | −$1.33 | −$1.20 | 9.58% | — | — |
| Q3 2022 | Aug 10, 2022 | −$1.47 | −$1.60 | -9.09% | — | — |
| Q2 2022 | May 13, 2022 | −$1.20 | −$1.80 | -50.00% | — | — |
| Q1 2022 | Feb 14, 2022 | −$1.20 | −$1.60 | -33.33% | — | — |
| Q4 2021 | Dec 22, 2021 | −$1.27 | −$1.60 | -26.31% | $300,000.00 | — |
| Q3 2021 | Aug 13, 2021 | −$1.40 | −$1.40 | 0.00% | $325,000.00 | — |
| Q2 2021 | May 14, 2021 | −$1.93 | −$1.80 | 6.89% | $325,000.00 | — |

## Frequently Asked Questions

### When did Outlook Therapeutics (OTLK) last report earnings?

Outlook Therapeutics last reported on Aug 14, 2026, covering fiscal Q3 2026.

### Did OTLK beat earnings estimates?

No. Outlook Therapeutics reported EPS of −$0.14 for Q3 2026 against a −$0.08 estimate — a 75.00% miss.

### How much revenue did OTLK report last quarter?

Outlook Therapeutics reported $9,000.00 in revenue for Q3 2026, against a consensus estimate of $966,667.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).